[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641874":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":41,"collaborators":10,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Pyatigorsk City Clinical Hospital Number 1","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Dapagliflozin Group",null,"Patients receiving dapagliflozin 10 mg once daily starting at 1 month after off-pump CABG",[13],{"name":14,"affiliation":5,"role":15},"Samson S. Badalyan, MD, PhD","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+79614972949","sambadalyan@mail.ru",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Syune V. Markosyan, MD.","+79633876510","ssm8883@gmail.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Pyatigorsk","Stavropol Kray","357500","Russia","RU",{"type":34,"coordinates":35},"Point",[36,37],43.05036,44.05,{"lat":37,"lon":36},[40],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":15,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Samson Badalyan","Cardiologist, Principal Investigator","100641874",false,"NCT07601867","Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting","Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Artery Bypass Grafting: a Prospective Single-Center Study","DAPA-RV-CABG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Elective isolated off-pump coronary artery bypass grafting (OPCAB)\n* Left ventricular ejection fraction (LVEF) \\\u003C 50% documented on pre-operative echocardiography\n* Written informed consent\n\nExclusion Criteria:\n\n* Concomitant valve surgery\n* Emergency or urgent CABG\n* Conversion to on-pump during surgery\n* Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI)\n* Cardiogenic shock\n* More than moderate valvular heart disease\n* Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination)\n* Previous CABG or any prior cardiac surgery\n* Severe chronic kidney disease (eGFR \\\u003C 25 mL\u002Fmin\u002F1.73 m²)\n* Contraindication to SGLT2 inhibitors\n* Inability to obtain adequate echocardiographic windows\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":54,"type":55},72,"ESTIMATED","OBSERVATIONAL","This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg\u002Fday on right ventricular-pulmonary artery coupling measured by the TAPSE\u002FPASP ratio in 72 patients with left ventricular ejection fraction \\\u003C50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE\u002FPASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).",[59,60],"Heart Failure","Coronary Arterial Disease",[62,63,64,65,66,67,68,69,70],"OPCAB","Right Ventricle","SGLT2 inhibitor","Dapagliflozin","TAPSE\u002FPASP","Pulmonary vascular resistance","KCCQ-23","CABG","RV-PA coupling","2026-06-15",{"date":73,"type":74},"2026-06-17","ACTUAL",{"date":76,"type":55},"2026-07-01",{"date":78,"type":55},"2028-07-01",{"name":5,"class":6},1]